Search

Displaying results 3961 - 3970 of 4860 in total
  1. Drug

    Prolease-r-hFSH

    go.drugbank.com/drugs/DB05826
    Experimental

    It provides patients with long term therapeutic benefit from a single administration rather than multiple injections.

  2. Drug

    Lixmabegagene relduparvovec

    go.drugbank.com/drugs/DB16816
    Investigational

    It is under development for the treatment of GM1 gangliosidosis.[L45929]

  3. Drug

    GALE-301

    go.drugbank.com/drugs/DB17262
    Investigational

    It is made up of E39, an immunogenic peptide derived from the folate binding protein (FBP), and an immune adjuvant, granulocyte macrophage-colony stimulating factor (GM-CSF).[A254696,L44166,L44171]

  4. Drug

    RPI-MN

    go.drugbank.com/drugs/DB17957
    Experimental

    [A260132] Being developed by Nutra Pharma under the trade name PEPTERON, it is being investigated for the treatment of neurological and immune disorders.[L47107]

  5. Drug

    ROX-888

    go.drugbank.com/drugs/DB05364
    Experimental

    ROX-888 is ROXRO's lead compound which is currently in Phase 3 trials for the treatment of acute pain, including post-operative pain.

  6. Drug

    Daxdilimab

    go.drugbank.com/drugs/DB16391
    Investigational

    Daxdilimab is under investigation in clinical trial NCT04526912 (Treatment and Prevention of Acute Lung Injury (ALI) in Patients With COVID-19 Infection).

  7. Drug

    Sufentanil

    go.drugbank.com/drugs/DB00708
    ApprovedInvestigational

    It is administered by the intravenous, epidural and sublingual routes.

    International brands: Sufenta mite
  8. Drug

    Avacincaptad pegol

    go.drugbank.com/drugs/DB15165
    ApprovedInvestigational

    It was developed to treat an advanced form of age-related macular degeneration (AMD) called geographic atrophy (GA).

  9. Drug

    Nirogacestat

    go.drugbank.com/drugs/DB12005
    ApprovedInvestigational

    It was previously granted breakthrough therapy, fast track, and orphan drug designations for the treatment of desmoid tumors, and the final approval was based on positive results obtained in the Phase

  10. Drug

    Pirbuterol

    go.drugbank.com/drugs/DB01291
    ApprovedWithdrawn

    While it is recognized that beta-2 adrenergic receptors are the predominant receptors in bronchial smooth muscle, data indicate that there is a population of beta-2 receptors in the human heart, existing